在线客服: 点击这里给我发消息  新用户使用步骤:会员注册→充值→重新登入→进入资源
标题:Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.
时间:2019-11-16 15:27:50
DOI:10.1517/14740338.2015.975205
PMID:25363438
作者:Chalmer, Thor; Almdal, Thomas P; Vilsb?ll, Tina
关键词:adverse reactions; cancer; glucagon-like peptide-1; liraglutide; pancreas; pancreatitis; type 2 diabetes
出版源: Expert Opinion on Drug Safety ,14 (1) :171-180
摘要:Introduction: The glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, is a widely used drug for the treatment of type 2 diabetes. Liraglutide is one of several incretin-based agents that have been suggested to be associated with pancreatitis and pancreas cancer. The suspicion accelerated after publication of an autopsy study claiming increased incidences of several pathological changes in pancreata from patients with diabetes treated with incretin-based drugs. Areas covered: The aim of the present review is to give an overview of the pharmacology of liraglutide and provide a review of adverse reactions associated with liraglutide with a focus on the risk of pancreatitis and pancreas cancer. Expert opinion: When comprehensively reviewing the available literature, no clear and significant associations between liraglutide and pancreatitis and/or pancreas cancer seem evident. However, a recently published analysis suggests a trend toward a slightly elevated risk of pancreatitis with GLP-1 receptor agonists (including liraglutide), which may become statistical significant as more data become available. Well-established side effects are of gastrointestinal origin, typical mild-to-moderate and of transient character. The risk of hypoglycemia associated with liraglutide treatment is low.
大小:370 kb
页数:11 PAGES
下载: 点击下载
预览:

浏览器不支持嵌入PDF阅读,打开新页面在线阅读

目录:
  • Abstract
  • Introduction
  • Mechanism of action, including key PK and PD data
    • Clinical applications, including key efficacy data
    • Safety evaluation
      • Preclinical and clinical studies
      • Postmarketing data
      • Safety in special populations, including pharmacogenomics data
      • Comparison with safety of other drugs
  • Conclusions
  • Expert opinion
  • Declaration of interest
  • Bibliography

本页内容由网络收集而来,版权归原创者所有,如有侵权请及时联系